What are the recommended first‑line antihypertensive medications, including dosing and titration, for initiating treatment?

First-Line Antihypertensive Medications: Recommended Agents, Dosing, and Titration

For uncomplicated hypertension, initiate monotherapy with a thiazide/thiazide-like diuretic, ACE inhibitor (in non-Black patients), long-acting calcium channel blocker, or ARB, and titrate to standard doses over 2-4 weeks before adding a second agent if blood pressure targets are not achieved. 1

Initial Monotherapy Selection

The following agents are Grade A or B recommendations for first-line therapy in uncomplicated hypertension:

• Thiazide/thiazide-like diuretics (Grade A) - strongest evidence base
• ACE inhibitors (Grade B in non-Black patients; avoid as first-line in Black patients)
• Long-acting calcium channel blockers (Grade B)
• Angiotensin receptor blockers (ARBs) (Grade B)
• β-blockers (Grade B, but only in patients <60 years; NOT recommended as first-line in patients ≥60 years) 1, 2

Critical caveat: β-blockers are explicitly NOT recommended as first-line therapy for uncomplicated hypertension in patients ≥60 years old (Grade A), and α-blockers are NOT recommended as first-line agents for any uncomplicated hypertension (Grade A) 1.

When to Start Combination Therapy Initially

Combination therapy using 2 first-line agents should be considered as initial treatment (Grade C) when:

• SBP is ≥20 mm Hg above target, OR
• DBP is ≥10 mm Hg above target 1, 3

This approach is particularly supported for stage 2 hypertension (SBP ≥140 mm Hg and DBP ≥90 mm Hg), ideally using single-pill combinations to improve adherence 3, 4.

Exercise caution with initial combination therapy in:

• Elderly patients
• Frail individuals
• Those at risk for substantial BP drops 1

Titration Timeline and Strategy

The time to reach 50% of maximum BP-lowering effect is approximately 1 week for most antihypertensive agents 5. However, practical titration should occur over 2-4 weeks to assess full therapeutic response and tolerability.

Stepwise Titration Approach:

1. Week 1-2: Initiate at standard starting dose

2. Week 2-4: Assess BP response; if target not achieved with standard-dose monotherapy, either:

   • Increase to maximum effective dose of the initial agent, OR
   • Add a second first-line agent (preferred approach) 1

3. Subsequent visits: Add-on drugs should be chosen from first-line options (Grade B)

Preferred Combination Strategies

When adding a second agent, evidence-based combinations include:

Strongest evidence (Grade B):

• Thiazide/thiazide-like diuretic + dihydropyridine CCB
• Thiazide/thiazide-like diuretic + ACE inhibitor
• Thiazide/thiazide-like diuretic + ARB
• CCB + ACE inhibitor or ARB 1, 2

Grade C combinations:

• Dihydropyridine CCB + ACE inhibitor

Avoid these combinations:

• ACE inhibitor + ARB (Grade A - NOT recommended due to harm) 1, 3
• Nondihydropyridine CCB + β-blocker (Grade D - exercise caution) 1

Isolated Systolic Hypertension

For isolated systolic hypertension, initial therapy should be:

• Thiazide/thiazide-like diuretic (Grade A)
• Long-acting dihydropyridine CCB (Grade A)
• ARB (Grade B) 1

Special Populations

Very elderly (≥80 years) without diabetes or target organ damage:

• SBP threshold for initiating therapy is 160 mm Hg (Grade C) 1

Black patients:

• ACE inhibitors are NOT recommended as first-line therapy (Grade A)
• Prefer thiazide diuretics or CCBs 1

Practical Dosing Considerations

Avoid hypokalemia in patients treated with thiazide/thiazide-like diuretic monotherapy (Grade C) 1. Monitor potassium levels and consider potassium-sparing agents or ACE inhibitors/ARBs in combination to mitigate this risk.

If BP remains uncontrolled with 2 first-line agents at adequate doses, add a third agent from a different class (Grade D). At this point, investigate possible reasons for treatment resistance 1.

Key Pitfalls to Avoid

1. Underdosing: Many clinicians use lower doses than those proven effective in clinical trials 6. Use standard to maximum effective doses before declaring treatment failure.

2. Premature medication changes: Allow 2-4 weeks for full therapeutic effect before switching or adding agents 5.

3. Using non-first-line agents initially: Avoid α-blockers and β-blockers (in patients ≥60 years) as initial monotherapy 1.

4. Combining drugs with similar mechanisms: Never combine ACE inhibitor + ARB due to increased risk of adverse events without additional benefit 1, 3.

5. Ignoring adherence: Single-pill combinations significantly improve adherence and should be prioritized when using multiple agents 3, 4.